A.P. Pharma, Inc. — FY2012 Form 10-K Summary
Filing identity: The supplied filing is for A.P. Pharma, Inc., not Heron Therapeutics, Inc. It covers the fiscal year ended December 31, 2012, with unaudited quarterly data through the fourth quarter of 2012.
Business Context and Reporting Period
A.P. Pharma was a specialty pharmaceutical company developing Biochronomer polymer-based drug-delivery technology. Its lead candidate, APF530, was designed as a single subcutaneous injection of granisetron for prevention of acute chemotherapy-induced nausea and vomiting and delayed CINV in moderately emetogenic chemotherapy.
The company had no approved or commercialized products and generated no product revenue. APF530’s resubmitted New Drug Application was filed with the FDA in September 2012, with a PDUFA action date of March 27, 2013. The company owned worldwide rights and was building U.S. commercialization capabilities while seeking international partners.
Financial and Operating Metrics
| Metric | 2012 | 2011 | Change |
|---|---|---|---|
| Revenue | $0 | $0.6 million | Down 100% |
| Research and development expense | $15.0 million | $8.2 million | Up 83% |
| General and administrative expense | $8.8 million | $3.5 million | Up 151% |
| Operating loss | $23.8 million | $11.1 million | Worsened by $12.8 million |
| Loss from continuing operations | $24.4 million | $11.4 million | Worsened by $13.0 million |
| Net loss | $23.3 million | $11.8 million | Worsened by $11.5 million |
| Net loss per share | $0.10 | $0.10 | Unchanged |
| Cash used in operations | $17.0 million | $7.7 million | Use increased by $9.3 million |
| Cash and cash equivalents at year-end | $53.5 million | $18.0 million | Up $35.5 million |
Fourth-quarter 2012 revenue was $0. Operating expenses were $8.6 million, continuing-operations loss was $8.8 million, and net loss was $7.7 million, or $0.03 per share.
Year-end working capital was $49.9 million, total assets were $56.0 million, stockholders’ equity was $51.8 million, and accumulated deficit was $183.6 million. The company reported no long-term liabilities, although it had convertible notes payable to related parties with a year-end carrying value of approximately $0.5 million.
Financing activities provided $53.5 million in 2012, including approximately $50.5 million net proceeds from a July 2012 common-stock financing and $3.0 million from additional convertible notes. The notes had $4.7 million of principal outstanding, accrued interest of approximately $0.1 million, a 6% stated interest rate, and could be prepaid at holders’ option.
Material Changes Versus Prior Period
- Revenue fell to zero after termination of the Merial development and license agreement; 2011 revenue was $0.6 million.
- R&D spending increased substantially as the company addressed FDA issues, completed requested APF530 studies, and prepared the NDA resubmission.
- G&A expense increased due to higher headcount, stock compensation, consulting, professional fees, and pre-commercialization activities.
- Stock-based compensation increased to $5.7 million from $1.9 million, including accelerated vesting related to director resignations.
- Cash improved primarily because of equity and convertible-note financings, despite significantly higher operating cash use.
- A February 2013 arbitration decision determined that no further amounts were owed under a discontinued-business gross-profit guaranty. The company reversed a $1.1 million accrual as of December 31, 2012, contributing to the $1.1 million gain from discontinued operations.
- Shares outstanding increased to approximately 302.2 million at December 31, 2012 from 200.0 million at December 31, 2011. Additional dilution was possible from options, warrants, and convertible notes.
Guidance, Outlook, Risks, and Unusual Items
Management stated that cash resources were expected to fund planned operations into 2014. This estimate depended on the FDA decision, APF530 launch timing and costs, manufacturing scale-up, commercial success, and the company’s ability to raise additional capital. Management expected 2013 R&D expense to decline if APF530 was approved, but expected G&A expense to increase in support of commercialization.
- APF530 remained subject to FDA approval after a prior Complete Response Letter in March 2010. The resubmission addressed dosing-system, manufacturing, sterilization, analytical, metabolism, bioavailability, and QT-study matters.
- The Phase 3 trial demonstrated non-inferiority of the 10 mg dose to Aloxi for specified endpoints, but APF530 did not demonstrate superiority for delayed CINV in highly emetogenic chemotherapy.
- The company depended on a small number of third-party manufacturers, had no manufacturing facilities, and had no long-term agreements with those manufacturers. FDA inspection findings and scale-up requirements could delay approval or commercialization.
- The company had no sales organization with established commercialization experience and would need to build a U.S. sales force or engage partners.
- APF530 faced competition from Aloxi, generic granisetron and ondansetron, Sancuso, and other drug-delivery technologies.
- The company had recurring losses, negative operating cash flow, an accumulated deficit, and warned that additional funding might be required. Future financing could dilute stockholders or be unavailable on acceptable terms.
- The common stock traded over the counter after Nasdaq delisting and was subject to penny-stock restrictions and substantial price volatility.
- The company reported no material pending legal proceedings and no off-balance-sheet arrangements. Management and the independent auditor concluded that internal controls over financial reporting were effective.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the provided filing is A.P. Pharma, Inc., not Heron Therapeutics, Inc.
- Verify the FDA outcome for the APF530 NDA after the March 27, 2013 PDUFA date.
- Assess whether the $53.5 million cash balance was sufficient relative to the company’s $17.0 million annual operating cash burn and commercialization needs.
- Review the terms, conversion potential, security interests, and holder prepayment rights of the convertible notes.
- Quantify potential dilution from approximately 86.3 million options, 84.4 million warrants, and shares issuable under convertible notes.
- Evaluate third-party manufacturing readiness, FDA remediation, commercial-scale production costs, and supply concentration.
- Distinguish recurring operating performance from the non-recurring $1.1 million discontinued-operations gain related to the arbitration decision.